2022TiP Stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV).

Authors :: Zhang, T.
Woldu, S.
Qin, Q.
Cole, S.
Arafat, W.
Jiang, C.
Wang, J.
Courtney, K.
DeVilbiss, A.
Ploski, R.
Hannan, R.
Yang, D.
Garant, A.
Tachibana, I.
Gaston, K.
Wang, A.Z.
Margulis, V.
Lotan, Y.
Desai, N.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1165-S1165. 1p.
Publication Year :: 2024

Subjects :: *CANCER invasiveness
*NEOADJUVANT chemotherapy
*BLADDER cancer
*CISPLATIN
*RADIOTHERAPY

Full Text Access

Tools